Virtual Library

 x 
My Library Virtual Library FAQ

Start Your Search

S. Ren



Author of

  • +

    P2.21 - Poster Session 2 - Diagnosis and Staging (ID 170)

    • Event: WCLC 2013
    • Type: Poster Session
    • Track: Prevention & Epidemiology
    • Presentations: 1
    • +

      P2.21-011 - Persistent Ground-Glass Opacity Lung Nodules < 20 mm in Diameter at CT: Histopathologic Comparisons with imaging features (ID 2357)

      09:30 - 09:30  |  Author(s): S. Ren

      • Abstract

      Background
      Differentiation of atypical adenomatous hyperplasia (AAH), adenocarcinoma in situ (AIS), minimally invasive adenocarcinoma (MIA), and invasive adenocarcinoma(IA) on computed tomography (CT) is useful for determining ‘‘follow-up or resection’’ strategies for lesions displaying ground-glass opacity nodules(GGN). The purpose of this study is to compare the morphologic features of persistent GGNs of <20 mm in diameter at thin-section CT (TSCT) with histopathology.

      Methods
      Jan 2010 and Dec 2012, a total of 200 nodules in 191 resected GGNs that were evaluated with TSCT were included in this study. Correlations between histopathology and CT characteristics were examined.

      Results
      The nodules included 45 AAH (22.5%), 99AISs (49.5%), 11 MIAs (5.5%), and 45 invasive adenocarcinomas (22.5%). The mean CT value (P < .0001), size of nodule (P < .0001) were significant factors that differentiated AAH lesions from invasive adenocarcinoma or AIS or MIA. While the size of nodule (P < .0001) and mass of nodule (P < .0.001) were significant factors that differentiated invasive adenocarcinoma from AIS or MIA.

      Conclusion
      Size of nodule less than 10 mm and mean CT value less than -510Hu are determinants of AAH, while size and mass of the nodule are determinants of invasive adenocarcinoma in Chinese population.

  • +

    P3.06 - Poster Session 3 - Prognostic and Predictive Biomarkers (ID 178)

    • Event: WCLC 2013
    • Type: Poster Session
    • Track: Biology
    • Presentations: 1
    • +

      P3.06-025 - T790M mutation associated with better efficacy of continuous EGFR-TKI treatment in advanced NSCLC patients with acquired resistance to EGFR-TKI (ID 2280)

      09:30 - 09:30  |  Author(s): S. Ren

      • Abstract

      Background
      The strategy for EGFR-TKI acquired resistance including continuous EGFR-TKI with chemotherapy or local therapy or chemotherapy alone. The aim of this study was to investigate the association of T790M mutation status with the efficacy of different modalities after acquired resistance to EGFR-TKI.

      Methods
      From Mar 2011 to Mar 2013, the advanced NSCLC patients who performed a rebiopsy after acquired resistance to EGFR-TKI in Shanghai Pulmonary Hospital were included into this study, Scorpion ARMS was used to detected the EGFR mutation status. SPSS 13.O was used to perform the statistical analysis.

      Results
      53 patients were enrolled in the study with a median age of 51.2 years old. 45.3% (25/53) were females and 54.7% (29/53) of patients had T790M mutation. Among them, 16 people with local disease progression received local therapy combined with TKI therapy, while 21 with a slow progress received chemotherapy plus TKI therapy. The median progression-free survival time (PFS1) of all patients according to RECIST criteria was 11.8 months. The median progression-free survival time (PFS2) of patients who received continuous EGFR-TKI treatment was 3.5 months (95% CI 2.689-4.311). Patients with T790M mutation had significantly longer PFS2 than those without T790M mutation (6.3 vs 3.0 months, p = 0.001), while there were no significant differences found in PFS1 between the two groups (13.0 vs 8.5 months, p = 0.999).

      Conclusion
      NSCLC patients who had T790M mutation after acquired resistance to EGFR-TKI benefited more from the continuous EGFR-TKI treatment and should be recommend to adopt this modality.